News
The U.S. Food and Drug Administration on Thursday publicly shared over 200 archived so-called complete response letters ...
By Stephanie Brown HealthDay ReporterTHURSDAY, July 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.
On July 10, 2025, the Food and Drug Administration (FDA) announced that it had published more than 200 complete response letters (CRLs), in ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
The US Food and Drug Administration (FDA) has announced the publication of more than 200 complete response letters (CRLs), ...
The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...
While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are ...
FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.
The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results